2024 World Conference on Lung Cancer (WCLC) - Posters-P1.08C.03 Updated Event-Free Survival of Tislelizumab Plus Chemotherapy Asneoadjuvant/adjuvant Therapy for Stage IIB-IIIC NSCLC (lungmark Study)

P1.08C.03 Updated Event-Free Survival of Tislelizumab Plus Chemotherapy Asneoadjuvant/adjuvant Therapy for Stage IIB-IIIC NSCLC (lungmark Study)

Back to course

Pdf Summary

The LungMark study evaluates the efficacy of neoadjuvant and adjuvant treatment using tislelizumab, a PD-1 inhibitor, combined with chemotherapy in patients with stage IIB-IIIC non-small cell lung cancer (NSCLC). Initially presented at the 2023 American Society of Clinical Oncology (ASCO) with promising results, the study highlights significant pathological responses among participants: a major pathological response (MPR) rate of 72.7% and a pathological complete response (pCR) rate of 47.7% within the surgical resection cohort.<br /><br />The study enrolled treatment-naïve patients and consisted of a treatment regimen involving 3-4 cycles of neoadjuvant therapy with tislelizumab (200mg), carboplatin, and either pemetrexed or nab-paclitaxel based on histology, followed by surgery and adjuvant tislelizumab monotherapy for one year. The primary endpoint focused on safety, with secondary endpoints including MPR, pCR, R0 resection rates, and event-free survival (EFS).<br /><br />The two-year EFS data showed notable results: 85.1% EFS rate at 12 months and 64.4% at 24 months. MPR achievers demonstrated more extended EFS compared to non-MPR individuals (39 months vs. 26 months). Surgical outcomes were favorable, with a 97.73% R0 resection rate, indicating complete tumor removal in most cases.<br /><br />The study concludes that the combination of tislelizumab and chemotherapy offers a substantial pathological response with favorable safety profiles for NSCLC patients undergoing neoadjuvant and adjuvant therapy. Long-term event-free survival benefits were observed, showcasing this approach's promise in managing advanced stages of lung cancer.

Asset Subtitle

Yao-Bin Lin

Meta Tag

Speaker Yao-Bin Lin

Topic Local-Regional NSCLC

Keywords

LungMark study

tislelizumab

PD-1 inhibitor

non-small cell lung cancer

neoadjuvant therapy

adjuvant therapy

major pathological response

event-free survival

R0 resection rate

chemotherapy